Progress Toward the Development of Agents to Modulate the Cell Cycle
Overview
Authors
Affiliations
With taxanes continuing to prove useful in the clinical treatment of cancer, the next generation of antimitotic agents has entered clinical trials. Other mechanisms awaiting proof-of-concept for the treatment of antiproliferative diseases include inhibition of cyclin-dependent kinases (Cdks). Flavopiridol and UCN-01 are continuing in clinical trials, and newer more selective Cdk inhibitors are now entering clinical evaluation.
Son E, Kim S, Kim Y, Lee Y, Kyung S, Jeong S BMC Complement Altern Med. 2019; 19(1):312.
PMID: 31729992 PMC: 6858790. DOI: 10.1186/s12906-019-2725-z.
Hu K, Liu C, Li J, Liang F Medchemcomm. 2018; 9(10):1663-1672.
PMID: 30429971 PMC: 6194498. DOI: 10.1039/c8md00223a.
Deng J, Chen W, Deng H J Fluoresc. 2016; 26(6):1987-1996.
PMID: 27488686 DOI: 10.1007/s10895-016-1892-2.
Yan C, Li F, Ma Y Int J Clin Exp Med. 2015; 8(8):14432-9.
PMID: 26550431 PMC: 4613116.
Long M, Wu J, Hao J, Liu W, Tang Y, Li X In Vitro Cell Dev Biol Anim. 2015; 51(10):1077-84.
PMID: 26194802 DOI: 10.1007/s11626-015-9937-4.